Want to see ABT full AI Analyst Report?
Operating Expense Breakdown
Details spending on R&D, selling and marketing, and general administration, revealing how Abbott allocates resources between innovation and commercial growth. Trends in these expenses show whether the company is investing to drive future products and market share or cutting costs to support margins, and they highlight efficiency gains or potential pressure on profitability.SG&A has stepped higher recently—peaking in Q1 2026—reflecting the Exact Sciences close, integration and financing costs that explain the $0.20 EPS dilution; expect elevated SG&A near-term as Abbott absorbs ~$3B of incremental sales. R&D is steadily increasing, aligning with management’s push on EP, CGM and pipeline trials and supports the call’s medium-term growth thesis. Meanwhile declining amortization shows legacy intangibles running off, modestly offsetting cash‑flow pressure from higher operating spend.
Date | Research and Development | Selling, General, and Administrative | Amortization |
|---|---|---|---|
Jun 30, 2026 | $892.00M | $4.03B | $658.00M |
Mar 31, 2026 | $767.00M | $3.74B | $422.00M |
Dec 31, 2025 | $735.00M | $3.13B | $422.00M |
Sep 30, 2025 | $766.00M | $3.05B | $420.00M |
Jun 30, 2025 | $725.00M | $3.09B | $420.00M |
Mar 31, 2025 | $716.00M | $3.06B | $420.00M |
Dec 31, 2024 | $749.00M | $2.91B | $465.00M |
Sep 30, 2024 | $713.00M | $2.90B | $470.00M |
Jun 30, 2024 | $698.00M | $2.94B | $471.00M |
Mar 31, 2024 | $684.00M | $2.96B | $472.00M |